Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Mini-Review

Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?

Bone Marrow Transplantation volume 28, pages 813–820 (2001)Cite this article

Abstract

The outlook for patients with mantle cell lymphoma is poor. The reported median survival in most published series is only 3 to 4 years, and even the most favorable prognostic groups have median survival rates of only 5 years, with no evidence of cure. The use of autologous and allogeneic stem cell transplantation in this disease has increased dramatically in recent years. Despite encouraging reports from single centers and registries, the impact of stem cell transplantation on the outcome for mantle cell lymphoma is unclear. Optimal first-line regimens for mantle cell lymphoma have yet to be defined, and it is therefore difficult to place the role of first remission transplantation in an appropriate context. Prospective randomized trials have been difficult to design and conduct in the absence of a well-defined ‘standard’ treatment. The role of stem cell transplantation as a salvage strategy is also unknown, although available data suggest that it does not improve survival in heavily pre-treated patients. In the absence of clear evidence for a survival advantage for patients receiving stem cell transplants for mantle cell lymphoma, entry into clinical trials should be a priority. Bone Marrow Transplantation (2001) 28, 813–820.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Stewart DA, Vose JM, Weisenberger DD et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma Ann Oncol 1995 6: 263–266

    Article  CAS  Google Scholar 

  2. Haas R, Brittinger G, Meusers P et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma Leukemia 1996 10: 1975–1979

    CAS  Google Scholar 

  3. Dreger P, von Neuhoff N, Kuse R et al. Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma Ann Oncol 1997 8: 401–403

    Article  CAS  Google Scholar 

  4. Ketterer N, Salles G, Espinouse D et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma Ann Oncol 1997 8: 701–704

    Article  CAS  Google Scholar 

  5. Kroger N, Hoffneckht M, Dreger P et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy Bone Marrow Transplant 1998 21: 55–57

    Article  CAS  Google Scholar 

  6. Blay J-Y, Sebban C, Surbiguet C et al. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients Bone Marrow Transplant 1998 21: 51–54

    Article  CAS  Google Scholar 

  7. Milpied N, Gaillard F, Moreau P et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience Bone Marrow Transplant 1998 22: 645–650

    Article  CAS  Google Scholar 

  8. Freedman AS, Neuberg D, Gribben JG et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long-term remission J Clin Oncol 1998 16: 13–18

    Article  CAS  Google Scholar 

  9. Khouri IF, Romaguera J, Kantarjian H et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem cell transplantation: an active regimen for aggressive mantle cell lymphoma J Clin Oncol 1998 16: 3803–3809

    Article  CAS  Google Scholar 

  10. Vose JM, Bierman PJ, Weisenberger DD et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma Biol Blood Marrow Transplant 2000 6: 640–645

    Article  CAS  Google Scholar 

  11. Decaudin D, Brousse N, Brice P et al. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3 year follow up study Bone Marrow Transplant 2000 25: 251–256

    Article  CAS  Google Scholar 

  12. Corradini P, Ladetto M, Astolfi M et al. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle cell lymphoma Br J Haematol 1996 94: 376–378

    Article  CAS  Google Scholar 

  13. Kroger N, Hoffnecht M, Kruger W et al. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma Ann Hematol 2000 79: 578–580

    Article  CAS  Google Scholar 

  14. Martinez C, Carreras E, Rovira M et al. Patients with mantle cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation Bone Marrow Transplant 2000 26: 677–679

    Article  CAS  Google Scholar 

  15. Khouri IF, Lee M-S, Romaguera J et al. Allogeneic hematopoietic transplantation for mantle cell lymphoma: molecular remissions and evidence of graft-versus-malignancy Ann Oncol 1999 10: 1293–1299

    Article  CAS  Google Scholar 

  16. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood 1994 84: 1361–1392

    CAS  Google Scholar 

  17. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization Classification of Diseases of the Hematopoietic and Lymphoid Systems Ann Oncol 1999 10: 1419–1432

    Article  CAS  Google Scholar 

  18. Zucca E, Stein H, Coiffer B . European Lymphoma Task force (ELTF): report of the workshop on mantle cell lymphoma (MCL) Ann Oncol 1994 5: 507–511

    Article  CAS  Google Scholar 

  19. Fisher RI, Dahlberg S, Nathwani BN et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study Blood 1995 85: 1075–1082

    CAS  PubMed  Google Scholar 

  20. Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes J Clin Oncol 1995 13: 2819–2826

    Article  CAS  Google Scholar 

  21. Norton AJ, Matthews J, Pappa V et al. Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period Ann Oncol 1995 6: 249–256

    Article  CAS  Google Scholar 

  22. Velders GA, Kluin-Nelemans JC, De Boer CJ et al. Mantle-cell lymphoma: a population-based study J Clin Oncol 1996 14: 1269–1274

    Article  CAS  Google Scholar 

  23. Zucca E, Roggero E, Pinotti G et al. Patterns of survival in mantle cell lymphoma Ann Oncol 1996 6: 257–262

    Article  Google Scholar 

  24. Weisenberger DD, Armitage JO . Mantle cell lymphoma – an entity comes of age Blood 1996 87: 4483–4494

    Google Scholar 

  25. Majlis A, Pugh WH, Rodriguez MA et al. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants J Clin Oncol 1997 15: 1664–1671

    Article  CAS  Google Scholar 

  26. Montserrat E, Bosch F, Lopez-Guillermo A et al. CNS involvement in mantle cell lymphoma J Clin Oncol 1996 14: 941–944

    Article  CAS  Google Scholar 

  27. Argatoff LH, Connors JM, Klasa RJ et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases Blood 1997 89: 2067–2078

    CAS  Google Scholar 

  28. Oinonen R, Franssila K, Teerenhovi et al. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients Eur J Cancer 1998 34: 329–366

    Article  CAS  Google Scholar 

  29. Bosch F, Lopez-Guillermo A, Campo E et al. Mantle cell lymphoma. Presenting features, response to therapy and prognostic factors Cancer 1998 82: 567–575

    Article  CAS  Google Scholar 

  30. Weisenberger DD, Vose JM, Greiner TC et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group Am J Hematol 2000 64: 190–196

    Article  Google Scholar 

  31. Vandenberghe E, De Wolf-Peeters C, Vaughan-Hudson G et al. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group Br J Haematol 1999 99: 842–847

    Article  Google Scholar 

  32. Foran JM, Rohatiner AZS, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma J Clin Oncol 2000 18: 317–324

    Article  CAS  Google Scholar 

  33. Foran JM, Cunningham D, Coiffier B et al. Treatment of mantle cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response Ann Oncol 2000 11: (Suppl. 1) 117–121

    Article  Google Scholar 

  34. Howard O, Gribben JG, Neuberg D et al. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma Blood 1999 94: 631a (Abstr.)

    Google Scholar 

  35. Hernandez L, Fest T, Cazorla M et al. P53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas Blood 1996 87: 3351–3359

    CAS  PubMed  Google Scholar 

  36. Greiner TC, Moynihan MJ, Chan WC et al. P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis Blood 1996 87: 4302–4310

    CAS  PubMed  Google Scholar 

  37. Yatabe Y, Suzuki R, Tobinai K et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive and cyclin D1-negative MCL-like B-cell lymphoma Blood 2000 95: 2253–2261

    CAS  PubMed  Google Scholar 

  38. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma New Engl J Med 1993 329: 987–994

  39. Armitage JO, Weisenberger DD . New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes J Clin Oncol 1998 16: 2780–2795

    Article  CAS  Google Scholar 

  40. Vandenberghe E, Ruiz de Elvira C, Isaacson P et al. Does transplantation improve outcome in mantle cell lymphoma (MCL)? A study from the EBMT Blood 2000 96: 482a (Abstr.)

    Google Scholar 

  41. Malone JM, Molina A, Stockerl-Goldstein K et al. High dose therapy and autologous hematopoietic cell transplantation for mantle cell lymphoma: the Stanford/City of Hope experience Proc Am Soc Clin Oncol 2001 20: 13a (Abstr.)

    Google Scholar 

  42. The Non-Hodgkin's Lymphoma Classification Project . A clinical evaluation of the International Lymphoma Study Group Blood 1997 89: 3909–3918

    Google Scholar 

  43. Romaguera JE, Dang NH, Hagemeister FB et al. Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle cell lymphoma (MCL) Blood 2000 96: 733a (Abstr.)

    Google Scholar 

  44. Jacquy C, Lambert F, Soree A et al. Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging? Bone Marrow Transplant 1999 23: 681–686

    Article  CAS  Google Scholar 

  45. Andersen NS, Donovan JW, Borus JS et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease Blood 1997 90: 4212–4221

    CAS  Google Scholar 

  46. Foran JM, Gupta RK, Cunningham D et al. Immunotherapy of follicular lymphoma with rituximab (chimeric anti-CD20 monoclonal antibody): a UK phase II trial with monitoring of molecular response Br J Haematol 2000 109: 81–88

    Article  CAS  Google Scholar 

  47. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence foe a role of both chemotherapy and rituximab infusion Blood 2000 96: 864–869

    CAS  Google Scholar 

  48. Van Besien KW, De Lima M, Giralt S et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect Bone Marrow Transplant 1997 19: 977–982

    Article  CAS  Google Scholar 

  49. Rondon G, Giralt S, Huh Y et al. Graft-versus- leukemia after allogeneic bone marrow transplantation for chronic lymphocytic leukemia Bone Marrow Transplant 1996 18: 669–672

    CAS  Google Scholar 

  50. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 1998 16: 2817–2824

    Article  CAS  Google Scholar 

  51. Sohn SK, Bensinger W, Holmberg L et al. High-dose chemotherapy with allogeneic or autologous stem cell transplantation for relapsed mantle cell lymphoma: the Seattle experience Proc Am Soc Clin Oncol 1997 17: 17a (Abstr.)

    Google Scholar 

  52. Adkins D, Brown R, Goodnough LT et al. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation Bone Marrow Transplant 1998 21: 97–99

    Article  CAS  Google Scholar 

  53. Molina A, Nademanee A, O'Donnell MR et al. Autologous and allogeneic stem-cell transplantation for poor-risk mantle cell lymphoma: the City of Hope experience Blood 1998 92: 459a (Abstr.)

    Google Scholar 

  54. Sohn SK, Baek JH, Kim DH et al. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL Am J Hematol 2000 65: 75–80

    Article  CAS  Google Scholar 

  55. Press OW, Eary JF, Gooley T et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Blood 2000 96: 2934–2942

    CAS  Google Scholar 

  56. King CA, Spellerberg MB, Ziiu D et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma Nat Med 1998 4: 1281–1286

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The author wishes to acknowledge the assistance of the Statistical Center of the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry who provided details of transplant activity in mantle cell lymphoma, and Dr Hillard M Lazarus for his critical review of this manuscript.

Author information

Authors and Affiliations

  1. University of Colorado Health Sciences Center, Denver, CO, USA

    JW Sweetenham

Authors
  1. JW Sweetenham
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sweetenham, J. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?. Bone Marrow Transplant 28, 813–820 (2001). https://doi.org/10.1038/sj.bmt.1703255

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703255

Keywords

This article is cited by

Search

Advanced search

Quick links